Results 11 to 20 of about 349 (107)

Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1. [PDF]

Diabetes, Obesity and Metabolism
ABSTRACT Aims To assess the added value of absolute anthropometric targets alongside percentage weight loss in the clinical management of obesity. Materials and Methods The phase 3a, 68‐week ...
Carel le Roux, Barbara McGowan, Luca Busetto   +2 more
exaly   +5 more sources

CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure [PDF]

Nature Metabolism
CagriSema is a combination of amylin (cagrilintide) and glucagon-like peptide-1 (semaglutide) analogues being developed for weight management. Here, we show that CagriSema blunts metabolic adaptation in rats. Quantifying CagriSema's action on energy intake and expenditure in rats we observe 12% weight loss with a 39% reduction in food intake.
Carel le Roux, Soren Snitker, Marc L. Reitman   +2 more
exaly   +5 more sources

CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 [PDF]

Hypertension
BACKGROUND: Fixed-dose combination of semaglutide/cagrilintide (CagriSema 2.4 mg/2.4 mg) has demonstrated significant and clinically relevant body weight reductions in adults with overweight or obesity compared with placebo. METHODS:
Dror Dicker, Arya M Sharma, Paolo Sbraccia   +2 more
exaly   +5 more sources

Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo. [PDF]

Annals of Medicine and Surgery
Background: Obesity remains a major global health challenge, driving demand for effective pharmacotherapies. Cagrilintide, a once-weekly amylin receptor agonist, and its fixed-dose combination with semaglutide ...
Yaseen M, Ameer A, Ali Z, Jamali JA, Kumar A, Basit Ali Siddiqui M, Kumari P, Hassaan M, Nanwani P, Abdul Basit M, Lohana N, Qureshi R, Tesfaye M.   +12 more
exaly   +3 more sources

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

, 2023
BACKGROUND: Combining the GLP-1 receptor agonist semaglutide with the long-acting amylin analogue cagrilintide has weight-loss benefits; the impact on glycated haemoglobin (HbA1c) is unknown. This trial assessed the efficacy and safety of co-administered
M Davies (7552133), S Macura (17025537), JP Frias (17025531), L Erichsen (17025534), SD Pedersen (17025540), S Deenadayalan (7804055), FK Knop (7783331), I Lingvay (7711226), C Mathieu (7738424)   +8 more
core   +10 more sources

Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema in Adults with Overweight or Obesity: A Bayesian Network Meta-Analysis

Journal of Clinical Question
Introduction: Incretin-based therapies, including glucagon-like peptide-1 receptor agonists and amylin analogues, have emerged as promising treatments for obesity.
Yange Meng, Ting Jin, Luping Ren, Michelle L. Thompson, Yue Wang   +4 more
doaj   +2 more sources

Comparative Efficacy and Safety of Semaglutide, Cagrilintide, and CagriSema for the Treatment of Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis

Journal of Clinical Question
Introduction: Type 2 diabetes mellitus (T2DM) is commonly associated with obesity and increased cardiometabolic risk, highlighting the need for therapies that optimize both glycemic control and weight management.
Ting Jin, Yange Meng, Luping Ren, Yue Wang   +3 more
doaj   +2 more sources

Incretin-based therapies for the treatment of obesity-related diseases

npj Metabolic Health and Disease
Obesity-related disability-adjusted life years (DALYs) are expected to increase by approximately 40% from 2020 to 2030. DALYs and mortality related to obesity are the consequence of multiple comorbidities such as cardiovascular (i.e., heart failure) and ...
Irene Caruso, Angelo Cignarelli, Gian Pio Sorice, Sebastio Perrini, Francesco Giorgino   +4 more
doaj   +2 more sources

Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents. [PDF]

Nutr Clin Pract
Abstract Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 receptor agonists have transformed the management of type 2 diabetes and obesity. Gastrointestinal (GI) adverse events are the most common limitation of these therapies and a leading cause of discontinuation ...
Singhani V, Ehsan M, Valencia S, Nadeem A, Moazzam E, Butsch WS, Garg S.   +6 more
europepmc   +2 more sources

Effects of Incretin-Based Therapies, Diet and Exercise Interventions, and Bariatric Surgery on Fat-Free Mass in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis. [PDF]

Diabetes Obes Metab
ABSTRACT Background Maintaining fat‐free mass (FFM) during weight loss is important to maintain a healthy body composition. This review examined changes in FFM during weight loss induced by diet and exercise interventions, incretin‐based therapies, and bariatric surgery, and assessed whether the relative loss of FFM differs by weight‐loss modality ...
Busk-Cirera L, Carlsen IØ, Madsen LB, Sandsdal RM, Jensen E, Jensen SBK, Torekov SS.   +6 more
europepmc   +2 more sources